In this view, for example, the identification of signaling pathways specifically controlling autophagy function and/or activation of canonical and noncanonical NF-κB signaling in TECs may allow to verify whether the novel mechanisms that Verhoeven and collaborators have shown to be therapeutically exploitable to support immunotherapy in melanoma may also be applied in other cancer settings, including those in which the global inhibition of autophagy has been reported to sustain tumor progression. The gene discussed is NFKB1; the disease is neoplasm.